Cadrenal Therapeutics, Inc. Common Stock
CVKD
$0.60
Change (1 day)
$32.55
Year High
$5.40
Year Low
Categories
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Stock split history for Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Cadrenal Therapeutics, Inc. Common Stock stock (symbol: CVKD) underwent a total of 1 stock splits.
The most recent stock split occured on Aug 20, 2024.
Annual Revenue
| Date | Splite | Multiple |
|---|---|---|
| 2024-08-20 | 1:15 | 1 |